NorthStar FDA Wednesday, December 21, 2022 0.00 Neutral

FDA Approves LEVOTHYROXINE SODIUM — NorthStar RxLLC

# FDA Approves NorthStar RxLLC's Generic Levothyroxine Sodium The U.S. Food and Drug Administration has approved NorthStar RxLLC's abbreviated new drug application for levothyroxine sodium oral formulation, potentially increasing competition in the thyroid hormone replacement market and providing patients with an additional generic treatment option for hypothyroidism. The approval is expected to expand market choice and could place downward pressure on pricing for this widely prescribed medication.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day